Efficacy and Tolerability of Tasipimidine in Sleepless Patients (Unitas)

Orion Pharma

Status and phase: Completed; Phase 2

Conditions: Insomnia

Treatments: Drug: Tasipimidine; Drug: Tasipimidine placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06956495

2022-502483-21-00 (EU Trial (CTIS) Number)

ISRCTN35042256 (Registry Identifier)

3110012

Details and patient eligibility

About

The goal of this trial is to learn if tasipimidine will help in the treatment of insomnia and how safe it is to use in sleepless people. Researchers will compare tasipimidine to a placebo (a look-alike substance that contains no drug) to see if tasipimidine works to treat insomnia. The trial consists of 2 consecutive parts and participants will be included either in Part 1 or Part 2. Part 2 will start only after Part 1 completion. Both parts include a screening period (up to 6 weeks), a treatment period (3 consecutive days and nights) and a post-treatment period (up to 10 days). Part 2 includes an additional 4 week extension part, where the participants take tasipimidine or placebo every evening at home and return to the sleep clinic for 2 last treatment nights. Participants will use equipment to record sleep parameters both at sleep clinic and home (Part 2) and a sleep diary is used.

Enrollment: 190 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent (IC) for participation in the study.
• Male or female subjects with age between 18 and 65 years.
• Insomnia disorder
• Self-reported history of the following on at least 3 nights per week and for at least 3 months prior to the screening: ≥ 30 minutes to fall asleep, subjective total sleep time ≤ 6 hours.
• Insomnia Severity Index© (ISI©) score ≥ 15 in Part 1 and ≥ 11 in Part 2.
• Usual bedtime between 21:00 and 02:00.
• Regular time in bed between 6 and 9 hours.
• Meeting predefined sleep parameter criteria in sleep recording on the 2 screening nights.
• Highly effective contraception.

Exclusion criteria

• Body mass index below 18.5 or above 40.0 kg/m2.
• Daytime napping ≥ 1 hour per day, and ≥ 3 days per week.
• Shift work within 2 weeks prior to the screening visit, or planned shift work during the study.
• Travel across ≥ 3 time zones within 2 weeks prior to the screening visit, or planned travel across ≥ 3 time zones during the study.
• Use of certain medications affecting central nervous system, e.g. sedatives or stimulans.
• Start of other new chronic medication within 14 days prior screening nights and planned change to an ongoing chronic medication during the study.
• Cognitive behavioural therapy (CBT) is allowed if the CBT started at least 1 month prior to the 1st screening night and the subject agreed to continue the CBT throughout the study.
• Diagnosed sleep-related breathing disorder, including chronic obstructive pulmonary disease and sleep apnoea.
• Acute or unstable psychiatric conditions.
• Alcohol or substance use disorder within 2 years prior to the screening visit or inability to refrain from drinking alcohol for at least 3 consecutive days.
• Significant cardiac disease.
• Significant postural hypotension.
• Heavy tobacco or other nicotine containing product use.
• Caffeine consumption ≥ 600 mg per day or regular caffeine consumption after 4 p.m.
• Heart rate < 50 bpm or > 100 bpm.
• Systolic blood pressure < 100 or > 160 mmHg or diastolic blood pressure < 50 or > 100 mmHg
• Abnormal 12-lead ECG finding.
• Significant abnormal laboratory findings including positive drug screen and presence of alcohol in breath test.
• Pre-planned elective surgery.
• Pregnant or lactating females.
• Blood donation or loss of significant amount of blood prior to the study.
• Participation in a drug study within 60 days prior to the study.
• Restless legs syndrome, circadian rhythm disorder, REM behaviour disorder, or narcolepsy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

190 participants in 5 patient groups, including a placebo group

Tasipimidine Dose level 1

Experimental group

Description:

Dose level 1

Treatment:

Drug: Tasipimidine

Tasipimidine Dose level 2

Experimental group

Description:

Dose level 2

Treatment:

Drug: Tasipimidine

Tasipimidine Dose level 3

Experimental group

Description:

Dose level 3

Treatment:

Drug: Tasipimidine

Placebo

Placebo Comparator group

Description:

Tasipimidine Placebo

Treatment:

Drug: Tasipimidine placebo

Tasipimidine Dose level 4

Experimental group

Description:

Dose level 4

Treatment:

Drug: Tasipimidine